This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/abbvie-stock-earnings-guidance-humira-arthritis-51651240769
- Order Reprints
- Print Article
In a quarterly earnings report out Friday, the drugmaker AbbVie cut its full-year earnings guidance, and a number of its key drugs missed Wall Street estimates.
The company’s first-quarter earnings were roughly in line with Wall Street expectations.
AbbVie (ticker: ABBV) reported adjusted diluted earnings of $3.16 per share, slightly beating…